Looking At Pfizer's Recent Unusual Options Activity


20-Year Pro Trader Reveals His "MoneyLine"

Ditch your indicators and use the "MoneyLine". A simple line tells you when to buy and sell without the guesswork. It’s a line on a chart that’s helped Nic Chahine win 83% of his options buys. Here's how he does it.


A financial giant has made a conspicuous bearish move on Pfizer. Our analysis of options history for Pfizer (NYSE:PFE) revealed 10 unusual trades. Delving into the details, we found 30% of traders were bullish, while 70% showed bearish tendencies. Out of all the trades we spotted, 7 were puts, with a value of $8,504,440, and 3 were calls, valued at $80,240.

Projected Price Targets

After evaluating the trading volumes and Open Interest, it's evident that the major market movers are focusing on a price band between $20.0 and $50.0 for Pfizer, spanning the last three months.

Analyzing Volume & Open Interest

Examining the volume and open interest provides crucial insights into stock research. This information is key in gauging liquidity and interest levels for Pfizer's options at certain strike prices. Below, we present a snapshot of the trends in volume and open interest for calls and puts across Pfizer's significant trades, within a strike price range of $20.0 to $50.0, over the past month.

Pfizer Option Activity Analysis: Last 30 Days

Largest Options Trades Observed:

SymbolPUT/CALLTrade TypeSentimentExp. DateStrike PriceTotal Trade PriceOpen InterestVolume
PFEPUTTRADEBULLISH11/10/23$35.00$4.2M551
PFEPUTTRADENEUTRAL11/10/23$35.00$4.0M5518.5K
PFEPUTTRADEBEARISH06/21/24$50.00$78.0K5710
PFEPUTTRADENEUTRAL01/19/24$50.00$67.7K2280
PFEPUTTRADENEUTRAL01/19/24$50.00$48.6K22860

Current Position of Pfizer

  • Trading volume stands at 13,151,033, with PFE's price down -2.0%, positioned at $30.62. RSI indicators show the stock to be may be approaching oversold. Earnings announcement expected in 83 days.

What Analysts Are Saying About Pfizer:

  • Consistent in their evaluation, Barclays keeps a Equal-Weight rating on Pfizer with a target price of $34.
  • UBS has revised its rating downward to Neutral, adjusting the price target to $34.
  • Maintaining their stance, Citigroup continues to hold a Neutral rating for Pfizer, targeting a price of $35.
  • JP Morgan has decided to maintain their Neutral rating on Pfizer, which currently sits at a price target of $34.
  • Wells Fargo persists with their Equal-Weight rating on Pfizer, maintaining a target price of $35.

Options trading presents higher risks and potential rewards. Astute traders manage these risks by continually educating themselves, adapting their strategies, monitoring multiple indicators, and keeping a close eye on market movements. Stay informed about the latest Pfizer options trades with real-time alerts from Benzinga Pro.


20-Year Pro Trader Reveals His "MoneyLine"

Ditch your indicators and use the "MoneyLine". A simple line tells you when to buy and sell without the guesswork. It’s a line on a chart that’s helped Nic Chahine win 83% of his options buys. Here's how he does it.


ENTER TO WIN $500 IN STOCK OR CRYPTO

Enter your email and you'll also get Benzinga's ultimate morning update AND a free $30 gift card and more!

Posted In: OptionsMarketsBZI-UOA